Lilly Completes Acquisition of Loxo Oncology
INDIANAPOLIS, Feb. 15, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Loxo Oncology, Inc. (NASDAQ: LOXO). The acquisition broadens the scope of Lilly's on... Biopharmaceuticals, Oncology, Mergers & Acquisitions Eli Lilly, Loxo Oncology (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 15, 2019 Category: Pharmaceuticals Source Type: news

Nevro Files Lawsuit for Patent Infringement Against Stimwave in the U.S.
REDWOOD CITY, Calif., Feb. 15, 2019 -- (Healthcare Sales & Marketing Network) -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has... Devices, Litigation Nevro Corp, Stimwave Technologies, Senza system, HF10 therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 15, 2019 Category: Pharmaceuticals Source Type: news

Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1
CEO Geert Cauwenbergh to Retire and Remain on Board of Directors MARLBOROUGH, Mass., Feb. 15, 2019 -- (Healthcare Sales & Marketing Network) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today announced that Gerrit Dispersyn, Dr. Med. Sc., currently Pre... Biopharmaceuticals, Oncology, Personnel Phio Pharmaceuticals, immuno-oncology, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 15, 2019 Category: Pharmaceuticals Source Type: news

Lipocine Inc. Announces FDA Clearance of IND to Commence Phase 2 Study of LPCN 1144 in Biopsy Confirmed NASH Subjects
SALT LAKE CITY, Feb. 14, 2019 -- (Healthcare Sales & Marketing Network) -- Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration ("FDA") indicated that the Phase 2 clinical stu... Biopharmaceuticals, FDA Lipocine, non-alcoholic steatohepatitis, LPCN 1144 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2019 Category: Pharmaceuticals Source Type: news

Boehringer Ingelheim and Lilly announce the CAROLINA(R) cardiovascular outcome trial of Tradjenta(R) met its primary endpoint of non-inferiority compared with glimepiride
Tradjenta (linagliptin) demonstrated no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk With a median follow-up of more than 6 years, CAROLINA adds evidence to the long-term safety profile o... Biopharmaceuticals, Endocrinology Eli Lilly, Boehringer Ingelheim, Tradjenta, linagliptin, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2019 Category: Pharmaceuticals Source Type: news

SK Biopharmaceuticals and Arvelle Therapeutics Announce Agreement to Develop and Commercialize Cenobamate in Europe
Arvelle Therapeutics to receive rights to develop and commercialize cenobamate, an investigational antiepileptic drug developed by SK Biopharmaceuticals, in Europe SK Biopharmaceuticals to receive upfront payment of $100 million and will be eligible for... Biopharmaceuticals, Licensing SK Biopharmaceuticals, Arvelle Therapeutics, cenobamate (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2019 Category: Pharmaceuticals Source Type: news

Burning Rock announces the completion of the Series C financing of RMB 850 million and strives to build an international leading tumor precision medicine brand
BALI, Indonesia and SHANGHAI, Feb. 14, 2019 -- (Healthcare Sales & Marketing Network) -- On February 14, 2019, Burning Rock held the signing ceremony and announced the closing of the Series C financing totaling RMB 850 million. The financing was led by GI... Diagnostics, Oncology, Venture Capital Burning Rock, precision medicine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 14, 2019 Category: Pharmaceuticals Source Type: news

Johnson and Johnson Announces Agreement to Acquire Auris Health, Inc.
Auris Health's Robotic Platform Expands Johnson & Johnson's Digital Surgery Portfolio NEW BRUNSWICK, N.J., Feb. 13, 2019 -- (Healthcare Sales & Marketing Network) -- Focused on creating the next frontier of surgery, Johnson & Johnson (NYSE: JNJ), today... Devices, Mergers & Acquisitions Johnson & Johnson, Auris Health, bronchoscopy, robotic (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2019 Category: Pharmaceuticals Source Type: news

ReWalk Announces Cigna as First Private U.S. Insurer to Adopt National Policy Change for Coverage of Personal Exoskeleton Devices
Cigna Transitions to Case-by-Case Review Process, Eliminating Non-Coverage Policy MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Feb. 13, 2019 -- (Healthcare Sales & Marketing Network) -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk" or the &q... Devices, Reimbursement ReWalk Robotics, stroke (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2019 Category: Pharmaceuticals Source Type: news

Bausch and Lomb Receives 510(k) Clearance For Use Of The Tangible(R) Hydra-PEG(R) Custom Contact Lens Coating Technology On Several Of Its Boston(R) Gas Permeable Lens Materials And Zenlens(TM) Family Of Scleral Lenses
Coating Technology offers Improved Lens Wettability for Patients with Challenging Vision Needs BRIDGEWATER, N.J., Feb. 13, 2019 -- (Healthcare Sales & Marketing Network) -- Bausch & Lomb, a leading global eye health company and wholly owned subsidiary ... Devices, Ophthalmology, FDA Bausch Health Companies, Bausch & Lomb, Tangible Hydra-PEG, scleral lens (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2019 Category: Pharmaceuticals Source Type: news

Alan M. Muney, MD, MHA Joins NEA As Venture Advisor
Healthcare Industry Veteran Brings Services Expertise to Global Venture Capital Firm's Robust Healthcare Practice MENLO PARK, Calif., Feb. 13, 2019 -- (Healthcare Sales & Marketing Network) -- New Enterprise Associates, Inc. (NEA), a leading global ven... Devices, Venture Capital, Personnel New Enterprise Associates (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2019 Category: Pharmaceuticals Source Type: news

Edwards Lifesciences Enters Into Agreement To Acquire CASMED
IRVINE, Calif. and BRANFORD, Conn., Feb. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today a... Devices, Monitoring, Mergers & Acquisitions Edwards Lifesciences, CAS Medical Systems, CASMED, FORE-SIGHT, Cerebral Oximeter (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 12, 2019 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves DARZALEX(R) (daratumumab) Split-Dosing Regimen
Revised product label allows for new administration option HORSHAM, Pa., Feb. 12, 2019 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FD... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, DARZALEX, daratumumab, multiple myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 12, 2019 Category: Pharmaceuticals Source Type: news

Check-Cap Announces Institutional Review Board Approval to Initiate U.S. Pilot Study of C-Scan(R)
ISFIYA, Israel, Feb. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical-stage medical diagnostics company advancing the develo... Devices, Gastroenterology, Radiology Check-Cap, C-Scan, ingestible capsule, colorectal cancer screening (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 12, 2019 Category: Pharmaceuticals Source Type: news

Clinical Trial Reports That Re-Treatment With A Single TearCare(R) Treatment Continues To Provide Relief For Patients With Dry Eye Disease
Study confirms significant results through 12 months of treatment with first personalized open-eye experience MENLO PARK, Calif., Feb. 12, 2019 -- (Healthcare Sales & Marketing Network) -- A new, single center, prospective clinical study published in t... Devices, Ophthalmology Sight Sciences, TearCare, dry eye, meibomian gland (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 12, 2019 Category: Pharmaceuticals Source Type: news

Pursuit Vascular's ClearGuard(R) HD Caps Selected as Top Infection Control Product for 2019
MAPLE GROVE, Minn., Feb. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Pursuit Vascular, Inc., manufacturer of ClearGuard® HD Antimicrobial Barrier Caps, today announced that Becker's Hospital Review selected ClearGuard HD caps as one of its &... Devices Pursuit Vascular, ClearGuard HD, Antimicrobial Barrier Caps, infection control (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 12, 2019 Category: Pharmaceuticals Source Type: news

BioDirection Receives Breakthrough Device Designation from FDA for Tbit(TM) System
Portable nanotechnology biosensor has the potential to predict positive CT scans following traumatic brain injury BOSTON, Feb. 11, 2019 -- (Healthcare Sales & Marketing Network) -- BioDirection, Inc., a privately held medical device company developing ... Devices, Diagnostics, Neurology, FDA BioDirection, Tbit, traumatic brain injury (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 11, 2019 Category: Pharmaceuticals Source Type: news

ImageMoverMD Raises $4 Million to Automatically Connect Medical Images with Electronic Patient Records
Medical imaging startup will expand network of health systems using its platform to connect and optimize medical image management MADISON, Wis., Feb. 11, 2019 -- (Healthcare Sales & Marketing Network) -- ImageMoverMD, a software platform that leverages... Healthcare Information Tech, Radiology, Venture Capital ImageMoverMD, Electronic Health Record, imaging (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 11, 2019 Category: Pharmaceuticals Source Type: news

FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
Cryptococcal Meningitis Included in FDA Tropical Disease Priority Review Voucher Program SAN DIEGO, Feb. 11, 2019 -- (Healthcare Sales & Marketing Network) -- Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening inf... Biopharmaceuticals, FDA Amplyx Pharmaceuticals, APX001, cryptococcosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 11, 2019 Category: Pharmaceuticals Source Type: news

Fresenius Medical Care North America Launches 2008T BlueStar(TM) Hemodialysis Machine Across the U.S.
Fresenius Medical Care North America Advances Renal Care with Next Generation Dialysis Delivery System Featuring More Than 30 Enhancements WALTHAM, Mass., Feb. 11, 2019 -- (Healthcare Sales & Marketing Network) -- Fresenius Medical Care North America's... Devices, Product Launch Fresenius Medical Care, 2008T BlueStar, hemodialysis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 11, 2019 Category: Pharmaceuticals Source Type: news

Pierangeli Clinic Initiates Program Providing Neovasc Reducer(TM) Procedure to Italian Patients with Refractory Angina
Second U.S. patient successfully undergoes Reducer procedure under compassionate use VANCOUVER, Feb. 11, 2019 -- (Healthcare Sales & Marketing Network) - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader... Devices, Interventional, Cardiology Neovasc, Reducer, angina (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 11, 2019 Category: Pharmaceuticals Source Type: news

Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPD
Market Development Veteran Lisa Rogan Joins Nuvaira's Executive Team MINNEAPOLIS, Feb. 11, 2019 -- (Healthcare Sales & Marketing Network) -- Nuvaira, a developer of novel therapeutic medical devices to treat obstructive lung diseases, announced today ... Devices, Venture Capital, Personnel Nuvaira, Lung Denervation, Targeted Lung Denervation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 11, 2019 Category: Pharmaceuticals Source Type: news

Foresee Pharmaceuticals Enters Exclusive License Agreement with Accord Healthcare
TAIPEI, Taiwan, Feb. 11, 2019 -- (Healthcare Sales & Marketing Network) -- An exclusive license agreement for the commercialisation of Foresee Pharmaceutical's (6576.TWO) novel FP-001 program (leuprorelin depot), Leuprolide Mesylate Injectable Suspension ... Biopharmaceuticals, Licensing Foresee Pharmaceuticals, Accord Healthcare, leuprorelin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 11, 2019 Category: Pharmaceuticals Source Type: news

OneTouch(R) Blood Glucose Monitoring System Accuracy Proven in New Long-Term Study
Research demonstrates clinical accuracy of OneTouch Select Plus® platform, and demonstrates the value of a continuous and systematic testing program to verify product performance for as long as it has been available to patients CHESTERBROOK, Pa., Fe... Devices, Diagnostics, Monitoring, Endcrinology LifeScan, OneTouch, blood glucose monitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 8, 2019 Category: Pharmaceuticals Source Type: news

Onkos Surgical(R) Announces the Release of MyTray(TM) a Breakthrough in Personalized Surgical Planning
PARSIPPANY, N.J., Feb. 7, 2019 -- (Healthcare Sales & Marketing Network) -- Onkos Surgical, Inc. announced today that it has launched MyTray, a fully integrated personal surgical planning solution that leverages preoperative imaging and the precision of s... Devices, Surgery, Personalized Medicine, Product Launch Onkos Surgical, MyTray, uDesign, Precision Oncology (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 7, 2019 Category: Pharmaceuticals Source Type: news

Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
HOUSTON, Feb. 7, 2019 -- (Healthcare Sales & Marketing Network) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hema... Biopharmaceuticals, Oncology, Personnel Marker Therapeutics, immunotherapy, immunotherapeutic (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 7, 2019 Category: Pharmaceuticals Source Type: news

Proteostasis Therapeutics Appoints Emmanuel Dulac and Kim Drapkin to Board of Directors
BOSTON, Feb. 6, 2019 -- (Healthcare Sales & Marketing Network) -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF... Biopharmaceuticals, Personnel Proteostasis Therapeutics, transmembrane conductance regulator, cystic fibrosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 6, 2019 Category: Pharmaceuticals Source Type: news

Lutronic And Syneron-Candela(R) Announce Settlement Of Patent Infringement Lawsuit
Candela and MGH Grant License; Comprehensive Settlement Reached BILLERICA, Mass. and WAYLAND, Mass., Feb. 5, 2019 -- (Healthcare Sales & Marketing Network) -- Syneron Medical Ltd. and Candela Corporation (collectively, "Syneron-Candela"), a g... Devices, Dermatology, Litigation Syneron-Candela, Lutronic (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 5, 2019 Category: Pharmaceuticals Source Type: news

Kallyope Inc. Appoints Brett Lauring As Chief Medical Officer
NEW YORK, Feb. 5, 2019 -- (Healthcare Sales & Marketing Network) -- Kallyope Inc., a leading biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, today announced that it has appointed Brett Lauring, M.D., Ph... Biopharmaceuticals, Personnel Kallyope, gut-brain (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 5, 2019 Category: Pharmaceuticals Source Type: news

Sojournix Appoints Ruth Thieroff-Ekerdt, M.D. As Senior Vice President And Chief Medical Officer
Key Appointment in the Advancement of SJX-653 as a Novel and Selective NK3 Antagonist in Clinical Development as a Once-Daily Non-Hormonal Treatment for Menopausal Vasomotor Symptoms, or "Hot Flashes" WALTHAM, Mass., Feb. 4, 2019 -- (Healthcar... Biopharmaceuticals, Personnel Sojournix, Hot Flashes, menopause (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 4, 2019 Category: Pharmaceuticals Source Type: news

Aratana Therapeutics Appoints Rhonda Hellums Chief Financial Officer
LEAWOOD, Kan., Feb. 4, 2019 -- (Healthcare Sales & Marketing Network) -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced t... Biopharmaceuticals, Personnel Aratana Therapeutics, Veterinary (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 4, 2019 Category: Pharmaceuticals Source Type: news

BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
TEL AVIV, Israel, Feb. 4, 2019 -- (Healthcare Sales & Marketing Network) -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that the U.S. Food and Drug Administration (FDA) has gra... Biopharmaceuticals, Oncology, FDA BioLineRx, BL-8040, CXCR4, Pancreatic Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 4, 2019 Category: Pharmaceuticals Source Type: news

Elekta: New Study to Learn From Every Cancer Patient Treated With Magnetic Resonance Radiation Therapy
The MOMENTUM study is a transformative approach to evaluating innovative medical technology UTRECHT, The Netherlands, Feb. 4, 2019 -- (Healthcare Sales & Marketing Network) -- Today, the international MR-linac Consortium announced the launch of the MOM... Devices, Oncology Elekta, MOMENTUM study, magnetic resonance radiation therapy, MR/RT therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 4, 2019 Category: Pharmaceuticals Source Type: news

argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor FcRn BREDA, the Netherlands and GHENT, Belgium and SAN DIEGO, F... Biopharmaceuticals, Drug Delivery, Licensing Halozyme Therapeutics, argenx , ENHANZE (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 4, 2019 Category: Pharmaceuticals Source Type: news

CHMP Recommends Approval of Praluent(R) (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
TARRYTOWN, N.Y. and PARIS, Feb. 4, 2019 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has a... Biopharmaceuticals, Cardiology, Regulatory Regeneron Pharmaceuticals, Sanofi, Praluent, alirocumab, ASCVD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 4, 2019 Category: Pharmaceuticals Source Type: news

New Partnership between Geo-Med, LLC and Stratis Medical Offers Veteran Administration Medical Centers and Department of Defense Military Treatment Facilities Exceptional Video Capsule Endoscopy
BOSTON, Feb. 1, 2019 -- (Healthcare Sales & Marketing Network) -- Geo-Med LLC, a Verified Service-Disabled Veteran-Owned Small Business supplier of medical products, is pleased to announce it has entered into an exclusive agreement with Stratis Medical, I... Devices, Gastroenterology, Distribution Stratis Medical, Capsule Endoscopy, MiroCam (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 1, 2019 Category: Pharmaceuticals Source Type: news

Natera Announces Agreement with One Lambda to Co-Distribute Its Kidney Transplant Rejection Test
Agreement Enhances Commercial Presence in Organ Transplant Centers SAN CARLOS, Calif., Feb. 1, 2019 -- (Healthcare Sales & Marketing Network) -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, to... Diagnostics, Distribution Natera, Thermo Fisher Scientific, One Lambda, Organ Transplant Assay (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 1, 2019 Category: Pharmaceuticals Source Type: news

CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
Company announces continuation of PAC203 study following third interim review SEATTLE, Feb. 1, 2019 -- (Healthcare Sales & Marketing Network) -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Company will withdraw its European Marketing Au... Biopharmaceuticals, Regulatory CTI BioPharma, pacritinib, myelofibrosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 1, 2019 Category: Pharmaceuticals Source Type: news

Israeli Start-up Laminate, Developer of a Vascular Support Solution for Dialysis Patients, Has Completed a Capital Raising Round of $12 Million
Among the investors in the current round are the Japanese company Asahi Kasei Medical, one of the largest manufacturers of dialyzers in the world, and private investors such as Shai Agassi, Mickey Boodaei, Yuval Tal, and Meir Barel Laminate has begun cl... Devices, Venture Capital Laminate Medical Technologies, VasQ, vascular access, dialysis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 31, 2019 Category: Pharmaceuticals Source Type: news

IGM Biosciences Appoints M. Kathleen Behrens, Ph.D., to Board of Directors
Dr. Kathy Behrens brings 35 years of biotech and investment industry experience and leadership MOUNTAIN VIEW, Calif., Jan. 31, 2019 -- (Healthcare Sales & Marketing Network) -- IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a g... Biopharmaceuticals, Oncology, Personnel IGM Biosciences, IgM antibodies, IgM antibody (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 31, 2019 Category: Pharmaceuticals Source Type: news

Magnolia Medical Announces $20 Million Series C Financing
Funding to accelerate company mission to establish new standard of care in sepsis testing accuracy SEATTLE, Jan. 30, 2019 -- (Healthcare Sales & Marketing Network) -- Magnolia Medical Technologies today announced a $20 million Series C financing round ... Devices, Venture Capital, Personnel Magnolia Medical Technologies, Steripath, Specimen Diversion Device (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 30, 2019 Category: Pharmaceuticals Source Type: news

CardioVax Announces Name Change to Abcentra
Reflects Strategic Commitment to a Novel Drug Target for Inflammatory Disease LOS ANGELES, Jan. 30, 2019 -- (Healthcare Sales & Marketing Network) -- CardioVax, a privately held, clinical-stage biopharmaceutical company developing novel antibody therap... Biopharmaceuticals Abcentra, CardioVax, low-density lipoprotein (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 30, 2019 Category: Pharmaceuticals Source Type: news

ArcherDX Acquires Baby Genes, a Genetics-Based Personalized Medicine Company
BOULDER, Colo., Jan. 30, 2019 -- (Healthcare Sales & Marketing Network) -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, is pleased to announce ... Diagnostics, Mergers & Acquisitions ArcherDX, Baby Genes, Anchored Multiplexed PCR, PCR (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 30, 2019 Category: Pharmaceuticals Source Type: news

Baylis Strengthens Global Commercialization Strategy with Senior Hire
TORONTO, Jan. 30, 2019 -- (Healthcare Sales & Marketing Network) - Baylis Medical is pleased to announce that seasoned marketing executive Gloria Yee has joined Baylis as its Vice President of Marketing. In her role, Gloria will be instrumental in expandi... Devices, Interventional, Cardiology, Personnel Baylis Medical (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 30, 2019 Category: Pharmaceuticals Source Type: news

ViaCyte Announces New Board Members
SAN DIEGO, Jan. 29, 2019 -- (Healthcare Sales & Marketing Network) -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced that following the recent $80 million Series D financing, the Company's Board of Directors has been restru... Regenerative Medicine, Personnel ViaCyte, islet replacement, diabetes, PEC-Direct, PEC-Encap (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 29, 2019 Category: Pharmaceuticals Source Type: news

Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
Addition of Phase 3-Ready Clinical Program Orphan Drug Designation for Proliferative Vitreoretinopathy, A Potentially Blinding Disease with No Approved Treatment Initial Clinical Trial Results Expected in 2020 LEXINGTON, Mass., Jan. 29, 2019 -- (H... Biopharmaceuticals, Ophthalmology, Mergers & Acquisitions Aldeyra Therapeutics, Helio Vision, Vitreoretinopathy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 29, 2019 Category: Pharmaceuticals Source Type: news

Nanospectra Biosciences Names Michael Brawer, M.D. as Chief Medical Officer
HOUSTON, Jan. 29, 2018 -- (Healthcare Sales & Marketing Network) -- Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced the appointment of Michael Brawer, M.D., as ... Devices, Oncology, Urology, Personnel Nanospectra Biosciences, nanomedicine, AuroLase, thermal ablation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 29, 2019 Category: Pharmaceuticals Source Type: news

Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
Veteran Pfizer researcher Andreas Maderna, Ph.D., joins the company SOUTH SAN FRANCISCO, Calif., Jan. 29, 2019 -- (Healthcare Sales & Marketing Network) -- Sutro Biopharma, Inc. (NASDAQ: STRO) today announced the appointment of Andreas Maderna, Ph.D., ... Biopharmaceuticals, Oncology, Personnel Sutro Biopharma, immunotherapy, immuno-oncology (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 29, 2019 Category: Pharmaceuticals Source Type: news

Biocept Launches Liquid Biopsy Kits Intended to Broaden Use of its Proprietary Technology Platform for High Sensitivity Detection of Circulating Tumor DNA
Target Selector™ kits are research-use-only (RUO) and designed to enable laboratories around the world to leverage Biocept's patented assay technology to perform cutting-edge liquid biopsy testing SAN DIEGO, Jan. 28, 2019 -- (Healthcare Sales & Marketin... Diagnostics, Oncology, Product Launch Biocept, liquid biopsy, Target Selector, circulating tumor DNA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 28, 2019 Category: Pharmaceuticals Source Type: news

Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President and CEO
Lead drug candidate IDL-2965 to enter clinical trials in early 2019 CAMBRIDGE, Mass., Jan. 28, 2019 -- (Healthcare Sales & Marketing Network) -- Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patien... Biopharmaceuticals, Personnel Indalo Therapeutics, nonalcoholic steatohepatitis, pulmonary fibrosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 28, 2019 Category: Pharmaceuticals Source Type: news